Have your own idea? Try our Stock Screener
U.S. Drug Retail Industry Analysis
UpdatedJun 18, 2026
DataAggregated Company Financials
Companies9
- 7D26.6%
- 3M3.3%
- 1Y-62.3%
- YTDn/a
In the last week, the Drug Retail industry is up 27%, with SRx Health Solutions up 58%. Meanwhile, Mangoceuticals actually underperformed within the industry, shrinking 7.8% in the last week. However, the industry is down 62% over the past year.
Industry Valuation and Performance
Has the U.S. Drug Retail Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 18 Jun 2026 | US$121.8m | US$1.9b | -US$59,333,311.04 | n/a | -2.1x | 0.07x |
| Sat, 16 May 2026 | US$119.2m | US$2.0b | -US$51,448,112.34 | n/a | -2.3x | 0.06x |
| Mon, 13 Apr 2026 | US$119.4m | US$2.0b | -US$53,310,095.91 | n/a | -2.2x | 0.06x |
| Wed, 11 Mar 2026 | US$141.0m | US$2.2b | -US$52,318,609.19 | 15.7x | -2.7x | 0.07x |
| Fri, 06 Feb 2026 | US$128.1m | US$2.1b | -US$34,428,153.21 | 14.1x | -3.7x | 0.06x |
| Sun, 04 Jan 2026 | US$95.4m | US$2.1b | -US$34,349,079.85 | 24x | -2.8x | 0.05x |
| Tue, 02 Dec 2025 | US$98.9m | US$2.2b | -US$34,817,200.75 | 18.9x | -2.8x | 0.05x |
| Thu, 30 Oct 2025 | US$2.0b | US$3.5b | -US$120,274,043.92 | 24.2x | -16.3x | 0.6x |
| Sat, 27 Sep 2025 | US$1.7b | US$3.5b | -US$120,223,236.21 | 20.7x | -14.2x | 0.5x |
| Mon, 25 Aug 2025 | US$12.2b | US$158.1b | -US$6,417,405,738.60 | 18.9x | -1.9x | 0.08x |
| Wed, 23 Jul 2025 | US$11.5b | US$158.1b | -US$6,426,931,248.53 | 41.1x | -1.8x | 0.07x |
| Fri, 20 Jun 2025 | US$11.2b | US$155.4b | -US$5,908,368,791.78 | n/a | -1.9x | 0.07x |
| Sun, 18 May 2025 | US$11.4b | US$155.4b | -US$5,906,493,038.11 | n/a | -1.9x | 0.07x |
| Tue, 15 Apr 2025 | US$10.9b | US$155.3b | -US$5,913,741,573.84 | n/a | -1.8x | 0.07x |
| Thu, 13 Mar 2025 | US$11.0b | US$153.8b | -US$8,983,780,689.60 | n/a | -1.2x | 0.07x |
| Sat, 08 Feb 2025 | US$10.2b | US$153.8b | -US$8,983,538,278.02 | n/a | -1.1x | 0.07x |
| Mon, 06 Jan 2025 | US$9.5b | US$151.0b | -US$8,784,036,651.31 | n/a | -1.1x | 0.06x |
| Wed, 04 Dec 2024 | US$9.4b | US$151.0b | -US$8,784,199,882.84 | n/a | -1.1x | 0.06x |
| Fri, 01 Nov 2024 | US$9.4b | US$151.0b | -US$8,683,676,681.45 | 80.2x | -1.1x | 0.06x |
| Sun, 29 Sep 2024 | US$9.0b | US$149.0b | -US$5,878,915,716.20 | 78x | -1.5x | 0.06x |
| Tue, 27 Aug 2024 | US$9.0b | US$147.8b | -US$5,898,391,163.28 | n/a | -1.5x | 0.06x |
| Thu, 25 Jul 2024 | US$9.8b | US$147.8b | -US$5,905,515,065.24 | n/a | -1.7x | 0.07x |
| Sat, 22 Jun 2024 | US$13.8b | US$146.9b | -US$6,131,584,509.17 | n/a | -2.3x | 0.09x |
| Mon, 20 May 2024 | US$15.9b | US$146.9b | -US$6,133,384,607.14 | 38.5x | -2.6x | 0.1x |
| Wed, 17 Apr 2024 | US$15.4b | US$146.9b | -US$6,142,349,622.57 | 38.5x | -2.5x | 0.1x |
| Fri, 15 Mar 2024 | US$18.4b | US$144.7b | US$499.5m | 31x | 36.7x | 0.1x |
| Sun, 11 Feb 2024 | US$19.4b | US$144.7b | US$499.3m | 33.4x | 38.8x | 0.1x |
| Tue, 09 Jan 2024 | US$21.8b | US$144.8b | US$444.8m | 39.7x | 49x | 0.2x |
| Thu, 07 Dec 2023 | US$18.7b | US$141.4b | -US$3,209,195,233.00 | 45.3x | -5.8x | 0.1x |
| Sat, 04 Nov 2023 | US$19.4b | US$164.8b | -US$4,853,479,314.00 | 67.3x | -4x | 0.1x |
| Mon, 02 Oct 2023 | US$19.5b | US$138.4b | -US$3,448,548,996.00 | 361.3x | -5.7x | 0.1x |
| Wed, 30 Aug 2023 | US$22.4b | US$138.4b | -US$3,448,637,070.00 | 361.3x | -6.5x | 0.2x |
| Fri, 28 Jul 2023 | US$27.0b | US$138.4b | -US$3,449,041,761.00 | 361.3x | -7.8x | 0.2x |
| Sun, 25 Jun 2023 | US$27.5b | US$135.5b | -US$3,277,999,295.00 | n/a | -8.4x | 0.2x |
Price to Earnings Ratio
-8.4x
Current Industry PE
- Investors are pessimistic on the American Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading close to its 3-year average PS ratio of 0.12x.
Past Earnings Growth
- The earnings for companies in the Drug Retail industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 76% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Comparison
How does U.S. Drug Retail compare with similar industries?
| US Market | 1.98% | |
| Consumer Staples | -1.93% | |
| Food and Staples Retail | -1.92% | |
| Drug Retail | 26.62% | |
| Food Distributors | 1.73% | |
| Big Box Super Stores | -1.92% | |
| Food Retail | -4.48% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SRXH SRx Health Solutions | US$0.20 | 58.3% +US$26.3m | -66.8% | PS5.6x | |
| YI 111 | US$4.41 | 1.1% +US$439.8k | -44.2% | PS0.02x |